Document Type

Journal Article

Publication Title

IBRO Reports

ISSN

2451-8301

Volume

6

First Page

147

Last Page

152

PubMed ID

31080907

Publisher

Elsevier Ltd

School

Centre of Excellence for Alzheimer’s Disease Research and Care / School of Medical and Health Sciences

RAS ID

28947

Funders

Funding information available at https://doi.org/10.1016/j.ibror.2019.05.001

Comments

Originally published as: Porter, T., Burnham, S. C., Milicic, L., Savage, G., Maruff, P., Sohrabi, H. R., ... Laws, S. M. (2019). COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults. IBRO Reports, 6, 147-152. Original publication available here

Abstract

The non-synonymous single nucleotide polymorphism (SNP), Val158Met within the Catechol-O-methyltransferase (COMT) gene has been associated with altered levels of cognition and memory performance in cognitively normal adults. This study aimed to investigate the independent and interactional effects of COMT Val158Met on cognitive performance. In particular, it was hypothesised that COMT Val158Met would modify the effect of neocortical Aβ-amyloid (Aβ) accumulation and carriage of the apolipoprotein E (APOE) ε4 allele on cognition in preclinical Alzheimer’s disease (AD). In 598 cognitively normal older adults with known neocortical Aβ levels, linear mixed modelling revealed no significant independent or interactional associations between COMT Val158Met and cognitive decline. These findings do not support previous associations between COMT Val158Met and cognitive performance and suggest this variant does not influence Aβ-amyloid or APOE ε4 driven cognitive decline in a well characterised cohort of cognitively normal older adults.

DOI

10.1016/j.ibror.2019.05.001

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

 
COinS